Malarone (Proguanil Hydrochloride, Atovaquone)

The combination works by targeting two essential parasite pathways. Atovaquone blocks the mitochondrial electron transport chain, stopping ATP production, while proguanil is converted to cycloguanil, which inhibits dihydrofolate reductase, disrupting folate metabolism and DNA synthesis. Together they produce a synergistic effect that rapidly kills blood‑stage parasites.

The dose of Malarone is set by the prescribing clinician based on the patient’s weight, age, indication (prophylaxis versus treatment), and renal or hepatic function. Standard adult regimens are defined in the product labeling, but the exact schedule must be individualized by a qualified health‑care professional.

Malarone is classified as pregnancy category B, indicating that animal studies have not shown risk but there are no adequate controlled studies in pregnant women. It may be used when the potential benefit justifies the potential risk. Small amounts can be excreted in breast milk, so breastfeeding mothers should discuss risks with their physician.

To order Malarone, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team then provides pricing, availability, shipping details and any required import documentation.

Compared with older agents such as chloroquine, Malarone offers a broader spectrum against chloroquine‑resistant Plasmodium falciparum and requires a shorter treatment course. Its dual‑mechanism reduces the chance of resistance development, but it may have more gastrointestinal side effects and requires careful consideration of drug interactions.

Malarone tablets should be stored at ambient temperature below 25 °C, in the original blister pack, protected from moisture and direct sunlight. Do not store in areas of high humidity or extreme heat to maintain product stability.

Malarone is taken orally with water, with or without food, as directed by the prescriber. For prophylaxis, tablets are usually started 1–2 days before entering a malaria‑risk area, continued daily throughout exposure, and taken for 7 days after leaving the area. For treatment, the full prescribed course is completed even if symptoms improve.

Serious risks include severe skin reactions such as Stevens‑Johnson syndrome, hepatic injury, hemolytic anemia in patients with glucose‑6‑phosphate dehydrogenase deficiency, and significant blood dyscrasias like neutropenia. Patients should be instructed to seek immediate medical attention if they develop rash, jaundice, dark urine, or unexplained fever.

Malarone should be avoided in individuals with known hypersensitivity to atovaquone, proguanil or any tablet components. It is contraindicated in patients with severe renal or hepatic impairment unless dose adjustment is made, and caution is advised for those with G6PD deficiency, pregnant women unless benefits outweigh risks, and young children under 5 kg without specialist guidance.